Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin Amid Strong Financial Position ...
In Q1 and Q2 of calendar 2025, Medicenna anticipates achieving several milestones in the MDNA11 program. These include completing monotherapy expansion and combination dose-escalation enrollment, ...
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback